Challenges in treatment of a patient suffering from neuroendocrine tumor G1 of the hilar bile duct: a case report

Biao Zhang

Dalian Medical University

Zhen Sun

Dalian Medical University

Xu Chen

Dalian Medical University

Bing Qi

Dalian Medical University

Qingkai Zhang

Dalian Medical University

Guixin Zhang

Dalian Medical University

Shuang Li (✉ shuangli@dmu.edu.cn)

Dong Shang

Dalian Medical University

Case report

Keywords: Biliary neuroendocrine tumors, Diagnosis, Treatment, R1 resection, Case report

Posted Date: April 1st, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-377428/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Gastroenterology on January 8th, 2022. See the published version at <https://doi.org/10.1186/s12876-021-02019-6>.

Abstract

Background

Neuroendocrine tumors (NETs) arise from neuroendocrine cells and are extremely rare located in the biliary tract. Currently, there are no guidelines for the diagnosis and treatment of biliary NETs. We present a case with NETs G1 of the hilar bile duct and the challenges for her treatment.

Case presentation

A 24-year-old woman was presented to our department with painless jaundice and pruritus, and the preoperative diagnosis was the perihilar bile duct cholangiocarcinoma. She underwent Roux-en-Y hepaticojejunostomy with excision of the extrahepatic biliary tree and radical lymphadenectomy. Unexpectedly, postoperative pathology showed a perihilar bile duct NETs G1 and microscopic invasion of the resected right hepatic duct. Then the patient received 3 cycles of adjuvant chemotherapy (Gemcitabine and tegafur-gimeracil-oteracil potassium capsule). At present, this patient has been following up for 20 months without recurrence or disease progression.

Conclusions

NETs of the biliary tract are difficult to diagnose preoperatively. The treatment for NETs G1 with R1 resection is still controversial yet may offer potential positive adjuvant chemotherapy. The diagnosis of NETs should be kept in mind by the surgeon for proper time management and more information about biliary NETs should be registered.

Introduction

Neuroendocrine tumors (NETs) are originated from the neuroendocrine cell system and have a steadily increased incidence from 1.09/100000 in 1973 to 6.98/100000 in 2012 [1,2]. NETs mainly occur in gastrointestinal tract (45.2%), respiratory system (30.2%) and pancreas (15.3%) [3]. The incidence of extrahepatic biliary neuroendocrine tumors (EBNETs) is extremely low and only accounts for 0.2%-2% of all gastrointestinal NETs [4]. The most familiar locations of EBNETs are found in the common hepatic duct and the distal common bile duct (19.2%), followed by the middle of the common bile duct (17.9%), the cystic duct (16.7%), and the proximal common bile duct (11.5%) [5]. NETs are histologically graded into well differentiated (grade 1, 2, or 3 NETs) or poorly differentiated (neuroendocrine carcinomas) tumors. Here we report a case of perihilar bile duct NETs G1.

Case Presentation

A 24-year-old woman was presented to our department with painless jaundice and pruritus for 6 days. Magnetic resonance imaging (MRI) in a local hospital indicated that biliary obstruction at the hepatic hilus and highly suspected hilar cholangiocarcinoma (Fig 1). The patient suffered yellow skin, itching all

over the body, dark urine, and light-colored stool. The patient had neither abdominal tenderness nor a palpable mass in the right upper quadrant of the abdomen. The patient had no family history of cancer or hepatobiliary disease. The laboratory examinations showed the following: Alanine aminotransferase, 22 IU/L (normal, 7-40IU/L); Aspartate transaminase, 27 IU/L (normal, 13-35IU/L); Total bilirubin, 193.1 umol/L (normal, $\leq$ 23.0 umol/L); Direct bilirubin, 153.5 umol/L (normal, $\leq$ 7.0 umol/L); Alkaline phosphatase, 231 IU/L (normal, 35-100 IU/L); Gamma-glutamyltransferase, 94 IU/L (normal, 7-45 IU/L). Tumor markers were within normal limits: carcinoembryonic antigen (CEA), 1.44 ng/ml (normal, 0-5 ng/ml); alpha-fetoprotein (AFP), 1.91 IU/L (normal, 0-5.8 IU/L); carbohydrate antigen 19-9 (CA-19-9), 20.7 IU/L (normal, 0-27 IU/L); CA-125, 14.6 IU/L (normal, 0-35 IU/L). An abdominal ultrasonography examination showed dilation of the hepatic bile duct and a solid hypoechoic mass approximately 24 mm $\times$ 10 mm in diameter located in the hepatic duct bifurcation (Fig 2). Abdominal contrast-enhanced computed tomography (CT) showed marked dilation of the intrahepatic bile duct, thickening of the common hepatic duct wall and luminal narrowing, and the tumor showed higher density than liver parenchyma in arterial-phase and portal-venous phase (Fig 2).

Subsequently, percutaneous transhepatic biliary drainage was performed to reduce jaundice and improve liver function, and the patient was referred for operation with the presumed diagnosis of the perihilar bile duct cholangiocarcinoma. At surgery, we detected a nodular mass in the perihilar bile duct without involving other tissues and the tumor completely blocking the bile duct lumen. Intraoperative frozen pathology showed no malignant tumor at the proximal cut end of the right and left hepatic duct and the distal cut end of the common bile duct. Roux-en-Y hepaticojejunostomy with excision of the extrahepatic biliary tree and radical lymphadenectomy were conducted. This procedure was considered curative since intraoperative frozen examination showed that the mass was mid atypia and the resection margin was negative. The jaundice was resolved completely and the patient was discharged 11 days after surgery without postoperative complications. A detailed postoperative immunohistochemical analysis revealed: the bile duct NET G1 with size 2 $\times$ 2 $\times$ 0.5 cm and tumor cells infiltrating in all layers, CD56(+), Syn(+), CgA(+), CK20(-), CK7(-), Ki-67 < 2% (Fig 3). Unexpectedly, a microscopic invasion of the resected right hepatic duct was observed in the final pathological examination. These results were so complicated and we face a challenge whether to continue to extend resection and adjuvant chemotherapy. After interdisciplinary discussion, we respected the patient's right to refuse second surgery and adjuvant chemotherapy was recommended. The patient received 3 cycles of adjuvant chemotherapy (Gemcitabine and tegafur-gimeracil-oteracil potassium capsule). At present, the patient has been followed up for 20 months without recurrence or disease progression (Fig 4).

Discussion

Preoperative diagnosis of EBNET is challenging because its lack of specific diagnostic indicators and extremely low incidence. Michalopoulos et al [6] reported that preoperative diagnosis was only in 4 cases of the 150 EBNET cases between 1959 and 2012. The diagnosis of EBNET mainly relies on the postsurgical pathological and immunohistochemical examination. For this patient, the following

questions were raised: 1. How should the surgeons make accurate preoperative diagnoses of EBNET? 2. Whether R1 resection of EBNET G1 requires further treatment and the therapeutic plan?

CgA can be elevated in both functional and non-functional NETs and can be a promising serum marker, but the sensitivity of CgA measurements in patient with NETs is only about 60-90% with a specificity of less than 50% [7]. Neuron-specific enolase (NSE) also has been utilized as a serum marker for NETs, and NSE can be elevated in 30-50% of NETs, especially in patients with high-grade tumors [7]. Functional NETs can produce some hormonal substances such as; somatostatin, polypeptides, serotonin, and calcitonin. It is useful to measure specific hormones in functional tumors. Both CA19-9 and CA-125 are commonly used serum tumor markers for the preoperative diagnosis of cholangiocarcinoma [8]. However, Wang HH et al [9] reported that the positivity of CA19-9 was only 15.0%, CA72-4 was 7.5%, CEA was 17.5%, and AFP was 15.0% in primary hepatic neuroendocrine tumors. Furthermore, serum tumor markers are normal in most EBNET G1/G2, but they tend to be higher than normal levels in EBNET G3 or extrahepatic biliary neuroendocrine carcinomas [10-14]. Our patient with the hilar bile duct NETs G1 had serum tumor markers were within normal limits.

Study [11] showed that the shape of EBNET could be divide into nodular, intraductal-growing, and periductal-infiltrating type. The imaging manifestations of enhanced CT in arterial-phase were as follows: (1) intraductal-growing type of EBNET indicated a higher density than the hepatic parenchyma, and this was helpful for distinguishing from the intraductal-growing type of cholangiocarcinoma showing a lower density than the hepatic parenchyma; (2) nodular type mainly shows equal density compared to hepatic parenchyma; (3) periductal-infiltrating type shows thickening of the bile duct wall and sudden blockage, which was similar to the distal bile duct cholangiocarcinoma. The imaging manifestations of MRI were as follows: (1) T1WI indicated that all tumors were lower SI than the hepatic parenchyma; (2) T2WI indicated that 80% of tumors were higher SI than the hepatic parenchyma; (3) DWI indicated that all tumors were higher SI than the hepatic parenchyma. The MRI manifestations of our patient were consistent with the study (Fig 1).

With advance technology, endoscopic and biopsy techniques can be used for preoperative diagnosis of EBNET. Lesions can be detected and biopsied by choledochoscopy, endoscopic retrograde cholangiopancreatography (ERCP), endoscopic ultrasound (EUS), and SpyGlass. Sano et al [15] firstly reported a case of well-differentiated EBNET diagnosed successfully by EUS-guided fine-needle aspiration biopsy. Besides that, biliary brush cytology has been widely used in the preoperative diagnosis of biliary diseases, that cytology of bile and bile duct brush specimens were also helpful for preoperative diagnosis of NET [10,16].

The unexpected pathological examination challenging us to give proper treatment. A multidisciplinary discussion proposed four options for this patient: (1) A second operation should be performed, and the entire tumor can be removed. But the new procedures would bring more surgical trauma to this patient. (2) The well-differentiated neuroendocrine cells are known to overexpress somatostatin receptors (SSR). The somatostatin analogs (SSA) or peptide receptor radionuclide therapy (PRRT) may be a good option

for patients with well-differentiated NET G1. Martyn et al [17] reported that compared with the placebo group, the SSA group could significantly prolong progression-free survival (PFS) in patients with metastatic enteropancreatic neuroendocrine tumors (Ki-67<10%). Ersin et al [18] found that PFS of the SSA group was 21 months, and was better than the group which had chemotherapy as their first-line treatment for NET (Ki-67≤20%). PRRT has become an effective treatment for the NETs that express sufficient SSR. Both ⁹⁰Y and ¹⁷⁷Lu were used as radioactive isotopes in PRRT for NET. ¹⁷⁷Lu-tetraazacyclododecanetetraacetic acid-octreotide (¹⁷⁷Lu-DOTATATE) therapy was recommended for patients with SSR-positive NET in the US in January 2018 and Europe in September 2017 [19]. To make sure SSR is positive, SSR imaging such as ⁶⁸Ga-DOTATATE PET/CT can be given initially before PRRT is administered. Studies [20,21] shows that ⁶⁸Ga-DOTATATE PET/CT was safer and efficient for diagnosis and treatment management of NET, and should be the preferred imaging method for preliminary diagnosis, selection of patients for PRRT, and localization of unknown primary tumors. (3) Systemic chemotherapy and targeted therapy may be a treatment choice for this patient, the chemotherapy can improve resectability and control tumor progression. However, chemotherapy is mainly used for patients with high-grade and metastatic NETs. And the role of chemotherapy is still undetermined in well-differentiated NETs, and still lack standard indications [22]. Many targeted drugs are under research, but few targeted drugs have entered phase III clinical trials. At present, only sunitinib and everolimus are FDA-approved targeted drugs for NETs [23]. Targeted therapy gives hope for low-grade and intermediate-grade NETs. A phase III trial [24] showed that everolimus could significantly improve PFS in patients with advanced, well-differentiated, and non-functional NETs. However, there is no specific evidence to clarify that chemotherapy or targeted therapy can benefit the hilar bile duct NET G1 with R1 resection. (4) NET G1 may be considered indolent, no further treatment required, and requires regular follow ups.

The patient chose no further therapy after three cycles of adjuvant chemotherapy and follow-up strictly at our outpatient service. At present, this patient has been following up for 20 months without recurrence or disease progression. Therefore, we believe that postoperative prophylactic intravenous chemotherapy is beneficial for NETs, especially for patients in G3. Many more clinical trials are ongoing, and these results will be clarified in the future. We know little of biliary NETs because of their rarity. There are currently no guidelines for the treatment of biliary NETs. Here we report a case of perihilar bile duct NETs G1 with R1 resection, and as far as we know this is the first report. More information about biliary NETs must be registered.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Informed written consent was obtained from the patient for publication of this report and any accompanying images.

Availability of data and materials

The datasets used during the current study are available from the corresponding author on reasonable request.

Competing interests

All authors declare no conflict of interest.

Funding

This study was supported by the National Natural Science Foundation of China (No. 81873156, No82000075), Liaoning Province Education Foundation (No. LZ2019051) and National Natural Science Foundation of Liaoning (No. 2020-BS-195).

Author contributions

Biao Zhang and Zhen Sun wrote and corrected the manuscript; Xu Chen, Bing Qi reviewed and corrected the manuscript; Guixin Zhang, Qingkai Zhang and Dong Shang were the patient's surgeon; Shuang Li and Dong Shang supervised and edited the manuscript; all authors approved the final version of the manuscript.

Acknowledgements

Not applicable.

References

1. Cives M, Strosberg JR. Gastroenteropancreatic Neuroendocrine Tumors. *CA Cancer J Clin* 2018, 68:471-487.
2. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. *JAMA Oncol* 2017, 3:1335-1342.
3. Del Arco CD, Sastre J, Peinado P, Diaz A, Medina LO, Fernandez Acenero MJ. Neuroendocrine Neoplasms in Rare Locations: Clinicopathological Features and Review of the Literature. *Indian J Endocrinol Metab* 2018, 22:308-315.
4. Costin AI, Păun I, Păun M, Constantin VD, Vârcuș F. Primary neuroendocrine tumors - an extremely rare cause of obstruction of extrahepatic bile ducts: a case report. *Rom J Morphol Embryol*. 2017, 58:641-644.

5. Michalopoulos N, Papavramidis TS, Karayannopoulou G, Pliakos I, Papavramidis ST, Kanellos I. Neuroendocrine tumors of extrahepatic biliary tract. *Pathol Oncol Res* 2014, 20:765-775.
6. Hosoda K, Kobayashi A, Shimizu A, Kitagawa N, Ito T, Yamada A, Miyagawa S. Neuroendocrine tumor of the common bile duct. *Surgery* 2016, 160:525-526.
7. Oberg K, Couvelard A, Delle Fave G, Gross D, Grossman A, Jensen RT, Pape UF, Perren A, Rindi G, Ruszniewski P, et al. ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers. *Neuroendocrinology*. 2017, 105:201-211.
8. Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. *Gut* 2012, 61:1657-1669.
9. Wang HH, Liu ZC, Zhang G, Li LH, Li L, Meng QB, Wang PJ, Shen DQ, Dang XW. Clinical characteristics and outcome of primary hepatic neuroendocrine tumors after comprehensive therapy. *World J Gastrointest Oncol* 2020, 12:1031-1043.
10. Choi J, Lee KJ, Kim SH, Cho MY. Preoperative diagnosis of well-differentiated neuroendocrine tumor in common hepatic duct by brush cytology: A case report. *Diagn Cytopathol* 2019, 47:720-724.
11. Hong N, Kim HJ, Byun JH, Kim SY, Kim KW, Kim JH, Hong SM. Neuroendocrine neoplasms of the extrahepatic bile duct: radiologic and clinical characteristics. *Abdom Imaging* 2015, 40:181-191.
12. Zhang L, Wan D, Bao L, Chen Q, Xie H, Xu S, Lin S. Neuroendocrine carcinoma in the extrahepatic biliary tract: A case report and literature review. *Medicine (Baltimore)* 2018, 97:e11487.
13. Kihara Y, Yokomizo H, Urata T, Nagamine M, Hirata T. A case report of primary neuroendocrine carcinoma of the perihilar bile duct. *BMC Surg* 2015, 15:125.
14. Hoepfner L, White JA. Primary extrahepatic bile duct neuroendocrine tumor with obstructive jaundice masquerading as a Klatskin tumor. *J Surg Case Rep* 2017, 2017:rjx104.
15. Sano I, Kuwatani M, Sugiura R, Kato S, Kawakubo K, Ueno T, Nakanishi Y, Mitsuhashi T, Hirata H, Haba S, et al. Hepatobiliary and Pancreatic: A rare case of a well-differentiated neuroendocrine tumor in the bile duct with spontaneous regression diagnosed by EUS-FNA. *J Gastroenterol Hepatol* 2017, 32:11.
16. Ishida M, Okano K, Sandoh K, Ito H, Ikeura T, Mitsuyama T, Miyoshi H, Shimatani M, Takaoka M, Okazaki K, Tsuta K. Neuroendocrine carcinoma diagnosis from bile duct cytological specimens: A retrospective single-center study. *Diagn Cytopathol* 2020, 48:154-158.
17. Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, Cadiot G, Wolin EM, Capdevila J, Wall L, et al: Lanreotide in metastatic enteropancreatic neuroendocrine tumors. *N Engl J Med* 2014, 371:224-233.
18. Ozaslan E, Karaca H, Koca S, Sevinc A, Hacioglu B, Ozkan M, Ozcelik M, Duran AO, Hacibekiroglu I, Yildiz Y, et al: Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less. *Anticancer Drugs* 2017, 28:222-229.

19. Mittra ES. Neuroendocrine Tumor Therapy: (177)Lu-DOTATATE. *AJR Am J Roentgenol* 2018, 211:278-285.
20. Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, Lakhani V, Baum RP, Berlin J, Smith GT, et al. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. *J Nucl Med* 2016, 57:708-714.
21. Sanli Y, Garg I, Kandathil A, Kendi T, Zanetti MJB, Kuyumcu S, Subramaniam RM. Neuroendocrine Tumor Diagnosis and Management: (68)Ga-DOTATATE PET/CT. *AJR Am J Roentgenol* 2018, 211:267-277.
22. Khasraw M, Ananda S, Michael M. Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy. *Expert Rev Anticancer Ther* 2016, 16:391-401.
23. Vijayvergia N, Dasari A. Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms. *Curr Treat Options Oncol* 2020, 21:96.
24. Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. *The Lancet* 2016, 387:968-977.

Figures

Figure 1

Preoperative abdominal MRI of the patient. A: Magnetic resonance cholangiopancreatography (MRCP) showed the tumor located at the hepatic duct bifurcation (blue arrow) and diffuse intrahepatic bile duct dilation. B: T1-weighted image (T1WI) showed thickened bile duct wall was lower signal intensity (SI) than the hepatic parenchyma and luminal narrowing (blue arrow). C: T2-weighted image (T2WI) showed the tumor was higher SI than the hepatic parenchyma (blue arrow). D: Diffusion-weighted image (DWI) showed the tumor was higher SI than the hepatic parenchyma (blue arrow).

Figure 2

Preoperative abdominal ultrasonography and CT of the patient. A: Abdominal ultrasonography depicts the dilation of bile duct (red arrow) and a solid hypoechoic mass located in the hepatic duct (blue arrow). B: Non-enhanced phase of CT shows marked dilation of the intrahepatic bile duct (red arrow) and a mass at the common hepatic duct (blue arrow). C: Arterial-phase CT indicates the thickened bile duct wall was of higher density than liver parenchyma and luminal narrowing (blue arrow). D: Portal-venous phase of CT indicates the thickened enhanced bile duct wall was of higher density than liver parenchyma and luminal narrowing (blue arrow).

Figure 3

Postoperative pathological and immunohistochemical examination. Hematoxylin-eosin staining shows that tumor cells grew in infiltrating glandular ducts and nests. Heterotypic cells were cubic, with round, dark-stained nuclei, acidophilic and abundant cytoplasm, and proliferation of surrounding fibrous tissue (A, $\times 200$). Immunohistochemical examination showed Ki-67 $< 2\%$ (B, $\times 200$), the positivity for CgA (C, $\times 200$), CD56 (D, $\times 200$) and Syn (E, $\times 200$), the negativity for CK-7 (F, $\times 200$) and CK-20 (G, $\times 200$).

Figure 4

MRCP and MRI of postoperative follow-up. This image indicates that the bile duct and the bile-intestinal anastomosis were unobstructed, the intrahepatic bile duct was not dilated, and there's no recurrence of the disease.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [consentform.pdf](#)
- [coverletter.doc](#)